Project Grant R44HL164199

Award Date 9/15/22
Completion Date 7/31/25
Dollars Obligated $2.3M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Putney, VT 05346, USA
Similar Awards
CPR Therapeutics Inc. received a $512,000 National Science Foundation Project Grant award under the NSF Technology, Innovation, and Partnerships program to develop an automated multimodal cardiopulmonary resuscitation system. The one-year award will support preclinical research and optimization studies using a swine model of cardiac arrest to design a next-generation proof-of-concept prototype. The system aims to improve outcomes for sudden cardiac arrest patients by integrating multiple...
This Project Grant from the National Science Foundation's Division of Industrial Innovation, under the Engineering program (CFDA 47.041), provides $256,000 to Colabs, Inc. to develop an automated airway and ventilator system that eliminates human operator variability during cardiopulmonary resuscitation (CPR). The system aims to reliably place an airway tube for ventilation, synchronize air delivery with chest compressions, and enable cardiac defibrillation at lower voltages through an electrode...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $793,956 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Resuscitation Innovations LLC, doing business as Advancedcpr Solutions LLC, located in Edina, Minnesota. The funding supports the development of innovative treatments to improve survival rates for patients experiencing refractory cardiac arrest, a condition where current interventions are ineffective. The project aims to advance "HEAD...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), focuses on developing and demonstrating a high-volume manufacturing technology for microfluidic oxygenators. The goal is to enable safer, simpler treatment of respiratory failure through extracorporeal membrane oxygenation (ECMO) therapy. The $294,063 award to Biomembretics, Inc. will fund a two-phase project to: 1) define the target...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI, CFDA 93.837 Cardiovascular Diseases Research) totaling $822,181 aims to advance personalized, physiology-directed cardiopulmonary resuscitation (CPR) strategies for pediatric in-hospital cardiac arrest. The research, to be conducted by The Children's Hospital of Philadelphia, will examine the physiological response to epinephrine administration during CPR and develop machine learning algorithms to predict...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $306,643 to develop a new extracorporeal membrane oxygenation (ECMO) pump designed for low-flow rates required for pediatric and neonatal patients. The primary objectives are to 1) design, develop, and bench test a pump that can operate in the 0.05 to 0.5 L/min flow rate range, which is an order of magnitude lower than...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $889,188 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant supports the development of a novel intravenous oxygen (IVO2) therapy using pH-responsive polymeric microbubbles to improve oxygenation and survival rates for cardiac arrest patients, particularly in cases of asphyxia-induced cardiac arrest. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,924 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Convergent Engineering, Inc. to develop a prototype decision support system for personalizing mechanical ventilation care. The proposed system aims to simplify the use of esophageal pressure measurements and provide decision support to optimize ventilator settings and prevent complications for ventilated patients. Key objectives include...
Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...

A MULTIMODAL INTEGRATED SYSTEM FOR IMPROVED CARDIOPULMONARY RESUSCITATION - ABSTRACT CPR THERAPEUTICS INC. IS DEVELOPING THE FIRST MULTIMODAL AUTOMATED SYSTEM FOR CARDIOPULMONARY RESUSCITATION (CPR). THIS TECHNOLOGY INTEGRATES AND SYNCHRONIZES MULTIPLE PUMP-MECHANISMS WITH ENHANCED DEFIBRILLATION, AND WILL BE THE FIRST DEVICE TO IMPROVE OUTCOMES OF PATIENTS IN CARDIAC ARREST WITH A NUMBER-NEEDED- TO-TREAT PREDICTIVE OF COMMERCIAL SUCCESS. IT WILL DO THIS WHILE ENHANCING PATIENT AND PROVIDER SAFETY. NATIONALLY, APPROXIMATELY 650,000 INDIVIDUALS SUFFER CARDIAC ARREST EACH YEAR. FIFTY YEARS AFTER THE DESCRIPTION OF CPR, SURVIVAL IS GENERALLY BELOW 10%, AND A SIGNIFICANT FRACTION OF RESUSCITATED PATIENTS ARE LEFT WITH NEUROLOGIC IMPAIRMENT. REMARKABLY, THE STANDARD-OF-CARE REMAINS MANUAL CHEST COMPRESSIONS PERFORMED BY RESCUERS WITH THEIR HANDS. IT HAS BEEN ESTIMATED THAT THE SOCIETAL COSTS RELATED TO OUT-OF-HOSPITAL CARDIAC ARREST ALONE MAY BE IN EXCESS OF $33 BILLION A YEAR IN THE US. WITHOUT QUESTION, CLINICALLY EFFECTIVE IMPROVEMENTS IN CPR ARE AMONG THE GREATEST UNMET MEDICAL NEEDS. ALL PREVIOUS ATTEMPTS AT EFFECTIVE CPR DEVICES HAVE: 1) FOCUSED ON ONLY ONE ENHANCEMENT AT A TIME, 2) HAD DISAPPOINTING OUTCOMES IN RANDOMIZED TRIALS, 3) CAUSE SKELETAL INJURIES IN MOST PATIENTS, AND 4) PROVIDE NO BENEFIT OVER MANUAL CPR. IN A SERIES OF PILOT STUDIES, CPR THERAPEUTICS DEMONSTRATED THAT COMBINATIONS OF CARDIAC OUTPUT- AND VENOUS RETURN-ENHANCING TECHNIQUES MAY OFFER ADDITIVE OR EVEN SYNERGISTIC BENEFITS TO HEMODYNAMICS. AS ENVISIONED, THE COMPANY'S MULTIFUNCTIONAL SYSTEM IS BASED ON THE CONCEPT THAT MULTIPLE CPR PUMP MECHANISMS, COMBINED WITH SYNCHRONIZATION OF DEFIBRILLATION AND PULSELESS ELECTRICAL ACTIVITY (PEA) CPR, WILL SYNERGIZE BOTH THE HEMODYNAMICS AND ELECTROPHYSIOLOGY. THESE APPROACH SHOULD SIGNIFICANTLY IMPROVE REAL-WORLD CLINICAL OUTCOMES. IN THIS DIRECT-TO-PHASE II PROJECT, CPR THERAPEUTICS WILL: 1) DESIGN AND BUILD A 3RD GENERATION PORCINE TEST-BED CAPABLE OF HIGH-FIDELITY MILLISECOND CONTROL OF THE MULTIMODAL CPR PUMP-MECHANISMS, 2) OPTIMIZE THE SYSTEM CONFIGURATION AND COMPONENT DESIGNS IN A PORCINE MODEL OF VENTRICULAR FIBRILLATION, AND 3) DESIGN AND BUILD A HUMAN CLINICAL PROTOTYPE UNDER A DESIGN-CONTROL AND QUALITY MANAGEMENT SYSTEM (QMS). THIS DEVICE WILL BE SUBJECTED TO STRUCTURAL AND FUNCTIONAL BENCH TESTING IN ANTICIPATION OF FILING FOR AN FDA IDE. IN ADDITION TO THE DEVELOPMENT OF THE TECHNOLOGY, THE PROJECT'S SCOPE-OF- WORK WILL ADD SIGNIFICANTLY TO OUR BASIC SCIENCE KNOWLEDGE OF THE INTERACTIONS BETWEEN CPR PUMP-MECHANISMS AND PATIENT-COMPONENT SYNCHRONIZATIONS.

Posted 9/15/22, 12:00 AM